Although the location of DLL3 expression on the pancreatic cancer cell is still unclear, its absence results in growth inhibition (123) This finding warrants further investigation on this molecule as a druggable target in PaCa. This evidence concerns the gene DLL3 and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.